Ultragenyx shares rallied after the Food and Drug Administration granted commercial approval to one of its gene therapies for treating a rare pediatric neurodevelopmental disorder.
Shares of Tempus AI, a firm that uses artificial intelligence for medical screening, rallied after estimates of its likely Medicare reimbursement rates for cancer products.
States haven't yet been able to obtain Covid-19 shots from the Centers for Disease Control and Prevention, delaying their distribution to millions of children through federal programs.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments